This thinner blood is more effective than aspirin in preventing heart attacks

Aspirin One of the most widely taken drugs in the world, after recommending it for decades as a means of protecting from heart attacks and strokes in patients at risk. However, a new study revealed that Clubidocral, the last thinner blood, or anticoagulant, is more effective in preventing serious heart attacks and strokes and does not carry any additional risk.

The result is the result of the research conducted by an international team of scientists from the United States, the United Kingdom, Switzerland, Australia and Japan. Their work is a twin-studying analysis-the study of collecting and analyzing the results of multiple smaller studies, with the aim of reaching a more reliable conclusion by looking at a greater amount of data. In total, this metastatic analysis of clinical data was considered of about 29,000 patients who were diagnosed with coronary artery disease (CAD), a condition in which fat accumulates in the arteries, which can lead to secondary effects such as heart attacks and heart failure.

Specialists have conducted a systematic search for medical databases such as PubMed, Scopus, Web of Science and Embase to find random experiences of CAD treatments published until April 12, 2025. The aim of the papers that compare the effectiveness of the fibers against Clubidogel in preventing heart deaths, hearts, and adults.

The analysis focused on seven investigations that included clinical information from people who suffer from confirmed cases from CAD treated with aspirin or clopidocr. After continuing 5.5 years, the researchers noted that those who received Clubidocrus had a 14 percent less risk of the main cardiovascular event compared to those treated with aspirin.

Ultimately, the team concluded that these results “add to the evidence” that Klopidqalle is superior to aspirin to prevent the main negative heart attacks and blood vessels. From the point of view of researchers, these results are supported by using Clopidogrel on aspirin in patients with the CAD facility to try to prevent them from taking great complications as a result of their condition, such as a heart attack. The results were published in the magazine Lancet.

In terms of deaths and risk bleeding, the perfect analysis concluded that the rates were similar in both groups, which confirms that Clubidocral is safe like aspirin.

The researchers wrote in the paper: “As far as we knew, Clubidoglyrell is the only remedy is the only anti -platelet treatment that has been constantly larger than aspirin without prejudice to safety,” the researchers wrote in the paper.

The discovery can transform medical guidance at the international level. CloPidogrel is a widely available drug with reasonable prices with reliable public publications, and properties that will make it easy to integrate into routine clinical practice. However, specialists stress that more comprehensive research is needed to assess the effectiveness of the cost of Clubidogrel and its performance in various groups in order to support their inclusion in treatment standards.

Cardiovascular diseases are the main cause of death in the world. According to the World Health Organization, it is estimated 17.9 million people Each year dies every year. More than four of every five of these deaths due to coronary heart disease or stroke. The new research indicates that Clopidogrel can become a major alternative to combating this problem in public health, which is still its occurrence all over the world.

This story was originally appeared on Wireless En español It was translated from Spanish.